+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Hemophilia Treatment Market - Global Forecast 2026-2032- Product Image
Hemophilia Treatment Market - Global Forecast 2026-2032- Product Image
Sale

Hemophilia Treatment Market - Global Forecast 2026-2032

  • Report

  • 190 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4829909
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Hemophilia Treatment Market is projected to reach USD 16.46 Billion in 2026. It is expected to continue growing at a CAGR of 6.86%, reaching USD 24.60 Billion by 2032.

Hemophilia treatment is moving from episodic bleeding control toward lifelong prevention, functional joint preservation, and measurable quality-of-life improvement. Hemophilia A, caused by factor VIII deficiency, and hemophilia B, caused by factor IX deficiency, remain rare but high-impact inherited bleeding disorders; peer-reviewed prevalence estimates place hemophilia A at about 17.1 cases per 100,000 males at birth and hemophilia B at about 3.8 cases per 100,000 males at birth.

For biopharma and treatment innovators, the hemophilia treatment market is defined by recombinant and plasma-derived clotting factors, extended half-life products, non-factor prophylaxis, bypassing agents, immune tolerance approaches for inhibitor management, and gene therapy. Demand is supported by earlier diagnosis, prophylaxis-oriented clinical guidelines, national hemophilia registries, and expanding hemophilia treatment center networks, while adoption is shaped by payer scrutiny, durability data, safety monitoring, and equitable access.

Transformative Shifts in Hemophilia Care

The hemophilia treatment landscape is undergoing a structural shift from on-demand factor replacement to prophylaxis-first care. Extended half-life factor VIII and factor IX therapies have reduced infusion frequency, while non-factor options, including bispecific antibody prophylaxis, have broadened prevention strategies, especially for patients with inhibitors and those seeking lower treatment burden.

Gene therapies for hemophilia A and B have added a potentially transformative, one-time treatment model, but uptake depends on durability of factor expression, liver safety monitoring, patient selection, outcomes-based contracting, and real-world evidence. This creates a market in which product differentiation increasingly depends on clinical convenience, long-term outcomes, adherence, safety profile, and total cost of care rather than factor activity alone.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical enabler across hemophilia treatment development and delivery. AI-supported pharmacokinetic modeling can personalize prophylaxis schedules, predict trough levels, and help reduce avoidable bleeding events, especially when combined with electronic infusion logs, electronic health records, laboratory data, and wearable activity signals.

For manufacturers and care systems, AI can improve clinical trial feasibility by identifying eligible patients, modeling bleeding risk, analyzing real-world evidence, and detecting safety signals earlier. It also supports supply forecasting for high-cost biologics and gene therapies, where inventory planning, cold-chain reliability, treatment center readiness, and patient-specific care pathways are critical to access and commercialization.

Regional Hemophilia Treatment Insights

Asia-Pacific is one of the most important regions for hemophilia treatment because China and India carry large patient populations with substantial underdiagnosis, while Japan, Australia, and South Korea provide mature reimbursement and advanced prophylaxis adoption. North America remains a global innovation hub, supported by specialized hemophilia treatment centers, strong clinical trial infrastructure, national surveillance activity, and early access to extended half-life products, non-factor prophylaxis, and gene therapy.

Latin America shows improving access through public procurement and national programs, with Brazil and Mexico playing central roles, but budget variability and unequal specialist access continue to affect treatment consistency. Europe combines high clinical standards with cost-sensitive reimbursement, health technology assessment, national tender systems, and strong registry activity that influence product positioning across EU and non-EU markets.

The Middle East, led by GCC health systems, is investing in specialty care, genetic counseling, advanced biologics, and digital health infrastructure, while broader access varies by national financing capacity. Africa has the largest unmet need relative to diagnosis and treatment availability; WFH-supported training, humanitarian aid, basic laboratory capacity, and registry development remain essential for moving care from acute bleeding management toward prophylaxis and long-term joint protection.

Group-Level Hemophilia Treatment Insights

ASEAN markets are expanding hemophilia diagnosis and access, but reimbursement maturity differs sharply between Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines. For industry vendors, ASEAN success depends on tiered access models, physician education, laboratory strengthening, and procurement strategies that fit diverse public health budgets and specialist distribution.

The GCC is positioned for faster adoption of high-value hemophilia therapies because centralized purchasing, specialist hospitals, genetic counseling programs, and digital health investment can support complex biologic and gene therapy pathways. The European Union is shaped by centralized regulatory science, national reimbursement decisions, cross-border clinical expertise, and the growing influence of EU-level health technology assessment, making comparative evidence, safety monitoring, and patient-reported outcomes essential.

BRICS countries represent scale: Brazil, Russia, India, China, and South Africa combine large patient pools with growing domestic manufacturing ambitions and persistent access gaps. G7 markets drive premium innovation, evidence standards, pharmacovigilance expectations, and early adoption of advanced therapies. NATO countries, many of which overlap with high-income European and North American systems, increasingly emphasize medicine security, resilient supply chains, emergency preparedness, and continuity of care for rare disease patients.

Country-Level Hemophilia Treatment Insights

The United States leads in clinical innovation, with the CDC estimating that as many as 33,000 males live with hemophilia, while Canada benefits from coordinated blood disorder networks, comprehensive care models, and structured reimbursement. Mexico is improving diagnosis and public access, though regional disparities persist, and Brazil remains Latin America’s most influential hemophilia treatment environment due to public-sector purchasing, national programs, and specialist care networks.

The United Kingdom, Germany, France, Italy, and Spain maintain advanced hemophilia treatment systems with strong specialist centers, guideline-based prophylaxis, and established reimbursement pathways, but payer assessment and budget impact guide uptake of premium therapies. Russia has a sizable diagnosed population and centralized procurement dynamics, although access conditions can vary by region and policy environment.

China is expanding treatment capacity through reimbursement reforms, hospital network development, and domestic biologic competition, while India faces a high underdiagnosed burden and needs stronger registry, affordability, factor availability, and prophylaxis infrastructure. Japan, Australia, and South Korea are mature Asia-Pacific markets with high clinical standards, advanced reimbursement, established hemophilia care expertise, and growing interest in therapies that reduce infusion burden and improve long-term joint health.

Actionable Recommendations for Industry Leaders

Industry vendors should prioritize differentiated evidence packages that combine annualized bleeding rate reduction, joint outcome data, inhibitor relevance, treatment burden, adherence, safety monitoring, and patient-reported quality of life. In a market increasingly shaped by high-cost biologics and gene therapy, value demonstration must extend beyond trial endpoints to real-world durability, safety, persistence, healthcare resource utilization, and long-term functional outcomes.

Commercial strategy should include early payer dialogue, outcomes-based agreements where appropriate, patient identification partnerships, treatment center readiness, and registry-enabled post-marketing evidence. Manufacturers should also invest in clinician and patient education for shared decision-making, because stakeholders must compare prophylaxis convenience, breakthrough bleed protection, gene therapy eligibility, monitoring requirements, reversibility considerations, and long-term uncertainty.

Research Methodology

This executive summary is based on triangulation of publicly available evidence from recognized health authorities, peer-reviewed epidemiology, hemophilia treatment guidelines, regulatory approvals, pharmacovigilance information, and market access patterns. Key reference categories include WFH resources, CDC hemophilia data, FDA and EMA approval records, national health technology assessment outputs, clinical guideline publications, and published prevalence studies.

Insights were validated through cross-comparison of disease burden, treatment adoption, reimbursement structures, clinical innovation, safety considerations, registry evidence, and regional access indicators. The analysis avoids speculative claims and emphasizes evidence-backed trends that are relevant to hemophilia treatment manufacturers, providers, payers, patient organizations, and policy stakeholders.

Conclusion: Future of Hemophilia Treatment

Hemophilia treatment is entering a new phase defined by prevention, personalization, and durable disease control. Extended half-life factors, non-factor prophylaxis, and gene therapy have expanded the clinical toolkit, but long-term success will depend on safety monitoring, payer-aligned value evidence, treatment center capability, and equitable access.

The next competitive advantage will come from integrating clinical innovation with real-world evidence, AI-enabled care optimization, and region-specific access strategies. Organizations that align product performance with patient outcomes, healthcare system affordability, and reliable supply continuity will be best positioned in the evolving hemophilia treatment market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Hemophilia Treatment Market, by Hemophilia Type
7.1. Introduction
7.2. Hemophilia A
7.3. Hemophilia B
7.4. Hemophilia C
8. Hemophilia Treatment Market, by Drug Class
8.1. Introduction
8.2. Desmopressin
8.3. Gene Therapies
8.4. Recombinant Coagulation Factor Concentrates
8.4.1. Recombinant Factor VIII
8.4.2. Recombinant Factor IX
8.5. Plasma-Derived Coagulation Factor Concentrates
8.6. Non-Factor Replacement Therapies
8.6.1. Monoclonal Antibodies
8.6.2. RNA-based Therapies
8.6.3. Antithrombin Inhibitors
8.7. Antifibrinolytic Agents
9. Hemophilia Treatment Market, by Administration Route
9.1. Introduction
9.2. Intravenous
9.3. Subcutaneous
9.4. Oral
10. Hemophilia Treatment Market, by Patient Age Group
10.1. Introduction
10.2. Pediatric
10.3. Adult
11. Hemophilia Treatment Market, by End User
11.1. Introduction
11.2. Home Healthcare
11.3. Hospitals
11.4. Specialized Clinics
12. Hemophilia Treatment Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Specialty Pharmacies
12.4. Retail Pharmacies
12.5. Online Pharmacies
13. Hemophilia Treatment Market, by Region
13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Latin America
13.5. Africa
13.6. Middle East
14. Hemophilia Treatment Market, by Group
14.1. NATO
14.2. G7
14.3. European Union
14.4. BRICS
14.5. ASEAN
14.6. GCC
15. Hemophilia Treatment Market, by Country
15.1. China
15.2. United States
15.3. Japan
15.4. Germany
15.5. India
15.6. United Kingdom
15.7. France
15.8. Australia
15.9. Italy
15.10. South Korea
15.11. Canada
15.12. Russia
15.13. Brazil
15.14. Spain
15.15. Mexico
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Takeda Pharmaceutical Company Limited
17.2. CSL Limited
17.3. F. Hoffmann-La Roche Ltd.
17.4. Bayer AG
17.5. Novo Nordisk A/S
17.6. Sanofi S.A.
17.7. Octapharma AG
17.8. BioMarin Pharmaceutical Inc.
17.9. Shanghai RAAS Blood Products Co., Ltd.
17.10. Alnylam Pharmaceuticals, Inc.
17.11. Belief BioMed Inc.
17.12. Biogen Inc.
17.13. Biotest AG
17.14. Catalyst Biosciences, Inc.
17.15. Chugai Pharmaceutical Co., Ltd.
17.16. Ferring B.V.
17.17. GeneVentiv Therapeutics, Inc.
17.18. Grifols, S.A.
17.19. HEMA Biologics, LLC
17.20. Hualan Biological Engineering Inc.
17.21. Intas Pharmaceuticals Ltd.
17.22. Kedrion S.p.A.
17.23. Medexus Pharma, Inc.
17.24. Nufactor, Inc.
17.25. Optum, Inc.
17.26. Pfizer Inc.
17.27. Sangamo Therapeutics, Inc.
17.28. Spur Therapeutics Limited
17.29. Swedish Orphan Biovitrum AB
17.30. uniQure N.V.
List of Figures
FIGURE 1. GLOBAL HEMOPHILIA TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL HEMOPHILIA TREATMENT MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL HEMOPHILIA TREATMENT MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL HEMOPHILIA TREATMENT MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 9. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
FIGURE 13. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 17. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL HEMOPHILIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL HEMOPHILIA TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL HEMOPHILIA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL HEMOPHILIA A MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL HEMOPHILIA A MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL HEMOPHILIA A MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL HEMOPHILIA B MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL HEMOPHILIA B MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL HEMOPHILIA B MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL HEMOPHILIA C MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL HEMOPHILIA C MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL HEMOPHILIA C MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL DESMOPRESSIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL DESMOPRESSIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL DESMOPRESSIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL GENE THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL GENE THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL GENE THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL RECOMBINANT FACTOR VIII MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL RECOMBINANT FACTOR VIII MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL RECOMBINANT FACTOR VIII MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL RECOMBINANT FACTOR IX MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL RECOMBINANT FACTOR IX MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL RECOMBINANT FACTOR IX MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL PLASMA-DERIVED COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL PLASMA-DERIVED COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL PLASMA-DERIVED COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL NON-FACTOR REPLACEMENT THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL NON-FACTOR REPLACEMENT THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL NON-FACTOR REPLACEMENT THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL RNA-BASED THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL RNA-BASED THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL RNA-BASED THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL ANTITHROMBIN INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL ANTITHROMBIN INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL ANTITHROMBIN INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL ANTIFIBRINOLYTIC AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL ANTIFIBRINOLYTIC AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL ANTIFIBRINOLYTIC AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL SPECIALIZED CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL SPECIALIZED CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL SPECIALIZED CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2017-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2017-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2017-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 97. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2017-2032 (USD MILLION)
TABLE 99. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 100. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2017-2032 (USD MILLION)
TABLE 101. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2017-2032 (USD MILLION)
TABLE 102. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 103. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 104. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 105. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 106. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2017-2032 (USD MILLION)
TABLE 108. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 109. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2017-2032 (USD MILLION)
TABLE 110. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2017-2032 (USD MILLION)
TABLE 111. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 112. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 113. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 114. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 115. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2017-2032 (USD MILLION)
TABLE 117. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 118. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2017-2032 (USD MILLION)
TABLE 119. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2017-2032 (USD MILLION)
TABLE 120. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 121. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 122. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 123. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 124. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 125. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2017-2032 (USD MILLION)
TABLE 126. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 127. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2017-2032 (USD MILLION)
TABLE 128. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2017-2032 (USD MILLION)
TABLE 129. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 130. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 131. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 132. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 133. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 134. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2017-2032 (USD MILLION)
TABLE 135. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 136. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2017-2032 (USD MILLION)
TABLE 137. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2017-2032 (USD MILLION)
TABLE 138. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 139. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 140. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 141. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 142. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 143. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 144. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2017-2032 (USD MILLION)
TABLE 145. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 146. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2017-2032 (USD MILLION)
TABLE 147. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2017-2032 (USD MILLION)
TABLE 148. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 149. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 150. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 151. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 152. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 153. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2017-2032 (USD MILLION)
TABLE 154. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 155. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2017-2032 (USD MILLION)
TABLE 156. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2017-2032 (USD MILLION)
TABLE 157. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 158. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 159. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 160. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 161. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 162. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2017-2032 (USD MILLION)
TABLE 163. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 164. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2017-2032 (USD MILLION)
TABLE 165. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2017-2032 (USD MILLION)
TABLE 166. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 167. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 168. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 169. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 170. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 171. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2017-2032 (USD MILLION)
TABLE 172. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 173. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2017-2032 (USD MILLION)
TABLE 174. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2017-2032 (USD MILLION)
TABLE 175. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 176. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 177. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 178. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 179. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 180. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2017-2032 (USD MILLION)
TABLE 181. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 182. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2017-2032 (USD MILLION)
TABLE 183. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2017-2032 (USD MILLION)
TABLE 184. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 185. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 186. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 187. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 188. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 189. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2017-2032 (USD MILLION)
TABLE 190. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 191. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2017-2032 (USD MILLION)
TABLE 192. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2017-2032 (USD MILLION)
TABLE 193. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 194. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 195. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 196. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 197. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 198. CHINA HEMOPHILIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 199. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2017-2032 (USD MILLION)
TABLE 200. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 201. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2017-2032 (USD MILLION)
TABLE 202. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2017-2032 (USD MILLION)
TABLE 203. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 204. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 205. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 206. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 207. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 208. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2017-2032 (USD MILLION)
TABLE 209. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 210. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2017-2032 (USD MILLION)
TABLE 211. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2017-2032 (USD MILLION)
TABLE 212. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 213. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 214. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 215. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 216. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 217. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2017-2032 (USD MILLION)
TABLE 218. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 219. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2017-2032 (USD MILLION)
TABLE 220. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2017-2032 (USD MILLION)
TABLE 221. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 222. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 223. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 224. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 225. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 226. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2017-2032 (USD MILLION)
TABLE 227. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 228. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2017-2032 (USD MILLION)
TABLE 229. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2017-2032 (USD MILLION)
TABLE 230. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 231. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 232. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 233. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 234. INDIA HEMOPHILIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 235. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2017-2032 (USD MILLION)
TABLE 236. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 237. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2017-2032 (USD MILLION)
TABLE 238. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2017-2032 (USD MILLION)
TABLE 239. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 240. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 241. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 242. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 243. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 244. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2017-2032 (USD MILLION)
TABLE 245. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 246. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2017-2032 (USD MILLION)
TABLE 247. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2017-2032 (USD MILLION)
TABLE 248. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 249. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 250. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 251. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 252. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 253. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2017-2032 (USD MILLION)
TABLE 254. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 255. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2017-2032 (USD MILLION)
TABLE 256. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2017-2032 (USD MILLION)
TABLE 257. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 258. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 259. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 260. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 261. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 262. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2017-2032 (USD MILLION)
TABLE 263. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 264. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2017-2032 (USD MILLION)
TABLE 265. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2017-2032 (USD MILLION)
TABLE 266. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 267. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 268. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 269. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 270. ITALY HEMOPHILIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 271. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2017-2032 (USD MILLION)
TABLE 272. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 273. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2017-2032 (USD MILLION)
TABLE 274. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2017-2032 (USD MILLION)
TABLE 275. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 276. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 277. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 278. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 279. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 280. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2017-2032 (USD MILLION)
TABLE 281. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 282. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2017-2032 (USD MILLION)
TABLE 283. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2017-2032 (USD MILLION)
TABLE 284. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 285. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 286. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 287. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 288. CANADA HEMOPHILIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 289. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2017-2032 (USD MILLION)
TABLE 290. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 291. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2017-2032 (USD MILLION)
TABLE 292. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2017-2032 (USD MILLION)
TABLE 293. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 294. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 295. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 296. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 297. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 298. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2017-2032 (USD MILLION)
TABLE 299. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 300. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2017-2032 (USD MILLION)
TABLE 301. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2017-2032 (USD MILLION)
TABLE 302. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 303. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 304. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 305. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 306. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 307. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2017-2032 (USD MILLION)
TABLE 308. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 309. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2017-2032 (USD MILLION)
TABLE 310. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2017-2032 (USD MILLION)
TABLE 311. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 312. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 313. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 314. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 315. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 316. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2017-2032 (USD MILLION)
TABLE 317. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 318. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2017-2032 (USD MILLION)
TABLE 319. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2017-2032 (USD MILLION)
TABLE 320. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 321. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 322. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 323. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 324. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 325. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2017-2032 (USD MILLION)
TABLE 326. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 327. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2017-2032 (USD MILLION)
TABLE 328. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2017-2032 (USD MILLION)
TABLE 329. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 330. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 331. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 332. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 333. GLOBAL HEMOPHILIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
TABLE 334. GLOBAL HEMOPHILIA TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • Takeda Pharmaceutical Company Limited
  • CSL Limited
  • F. Hoffmann-La Roche Ltd.
  • Bayer AG
  • Novo Nordisk A/S
  • Sanofi S.A.
  • Octapharma AG
  • BioMarin Pharmaceutical Inc.
  • Shanghai RAAS Blood Products Co., Ltd.
  • Alnylam Pharmaceuticals, Inc.
  • Belief BioMed Inc.
  • Biogen Inc.
  • Biotest AG
  • Catalyst Biosciences, Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • Ferring B.V.
  • GeneVentiv Therapeutics, Inc.
  • Grifols, S.A.
  • HEMA Biologics, LLC
  • Hualan Biological Engineering Inc.
  • Intas Pharmaceuticals Ltd.
  • Kedrion S.p.A.
  • Medexus Pharma, Inc.
  • Nufactor, Inc.
  • Optum, Inc.
  • Pfizer Inc.
  • Sangamo Therapeutics, Inc.
  • Spur Therapeutics Limited
  • Swedish Orphan Biovitrum AB
  • uniQure N.V.

Table Information

Report AttributeDetails
No. of Pages190
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 16.46 Billion
Forecasted Market Value ( USD ) by 2032 $ 24.6 Billion
Compound Annual Growth Rate6.8%
Regions CoveredGlobal
No. of Companies Mentioned30

Related Topics

Related Reports

Rare Hemophilia Factors - Global Strategic Business Report - Product Image

Rare Hemophilia Factors - Global Strategic Business Report

  • Report
  • 132 Pages
  • Global
From
Hemophilia Drugs - Global Strategic Business Report - Product Image

Hemophilia Drugs - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Hemophilia - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Hemophilia - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 115 Pages
  • Global
From
Hemophilia Market - Forecast from 2026 to 2031 - Product Image

Hemophilia Market - Forecast from 2026 to 2031

  • Report
  • 149 Pages
  • Global
From
Rare Hemophilia Factors Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F - Product Image

Rare Hemophilia Factors Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

  • Report
  • 180 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.